http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201021801-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46d7b4a93e19c0c20d10f83a38d0c98f |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate | 2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_166b86ccb3dd28d0ca69b6f6f62b7506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27553771ff7787db4cc245119a9c1742 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bda08619d69aeee128dc2612b771fab |
| publicationDate | 2010-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201021801-A |
| titleOfInvention | A pharmaceutical composition for the treatment of cancers |
| abstract | Disclosed herein is a pharmaceutical composition for treating cancers, comprising a synergistic effective amount of an O6-Methylguanine DNA methyltransferase (MGMT) inhibitor and an alkylating antineoplastic agent, wherein a combination index of the pharmaceutical composition is less than 1. IN one example, the MGMT inhibitor is n-Butulidenephthalide and the alkylating antineoplastic agent is carmustine (BCNU). The pharmaceutical composition is particularly useful for the treatment of human solid cancers, such as liver cancers, lung cancers, brain tumors, ovarian cancers, and colorectal cancers. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8927601-B2 |
| priorityDate | 2008-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.